Dishman Carbogen Amcis' Shanghai Facility Secures Drug Manufacturing License from NMPA
Dishman Carbogen Amcis Ltd. has announced that its Shanghai facility, CARBOGEN AMCIS (Shanghai) Co. Ltd., has successfully obtained a Drug Manufacturing License (DML) from the National Medical Products Administration (NMPA) in China. The facility, located in the Shanghai Chemical Industry Park (SCIP), is a fully self-supporting site equipped for early-phase research and development, pilot scale production and commercial GMP manufacture. It has a 40,000m² area and employs over 140 people, offering services ranging from raw materials to APIs, including high potency material handling and micronization. The site is built for flexibility, efficiency and scalability with equipment in four segregated units and reactor capacities from 50 to 6,300 litres.
Key Highlights
- Dishman Carbogen Amcis' Shanghai facility has received a Drug Manufacturing License from the NMPA.
- The facility is a fully self-supporting site equipped for early-phase research and development, pilot scale production and commercial GMP manufacture.
- The site is located in the Shanghai Chemical Industry Park (SCIP) and has a 40,000m² area.
- The facility offers services ranging from raw materials to APIs, including high potency material handling and micronization.
- The site is built for flexibility, efficiency and scalability with equipment in four segregated units and reactor capacities from 50 to 6,300 litres.